These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 9611063)

  • 1. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
    Saygili U; Uslu T; Erten O; Doğan E
    Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
    Giurgea NL; Pitrop M; Mihailovici MS
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-malignant potential epithelial tumors of the ovary: a clinicopathological study.
    Hassan E; Koumantaki Y; Stefanaki K; Matalliotakis I; Koumantakis E
    Eur J Gynaecol Oncol; 1998; 19(2):170-2. PubMed ID: 9611060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
    Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
    Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
    Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
    Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
    Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
    Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
    Zhang W; Wang L; Xin Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinicopathological features and risk factors of recurrence in patients with mucinous borderline ovarian tumors].
    Sun L; Song Y; Li N; Yuan GW; Sun YC; Li N; Ma SK; Zhang X; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):589-594. PubMed ID: 28835081
    [No Abstract]   [Full Text] [Related]  

  • 11. Mucinous carcinoma of the ovary. Clinicopathologic analysis.
    Kikkawa F; Kawai M; Tamakoshi K; Suganuma N; Nakashima N; Furuhashi Y; Kuzuya K; Hattori S; Arii Y; Tomoda Y
    Oncology; 1996; 53(4):303-7. PubMed ID: 8692534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
    Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
    Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
    Fan HY; Duan DM; Liu YF
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
    Cho HY; Kyung MS
    Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Borderline ovarian tumors].
    Ivanov S
    Akush Ginekol (Sofiia); 2002; 42(1):23-5. PubMed ID: 11935694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
    Chiesa AG; Deavers MT; Veras E; Silva EG; Gershenson D; Malpica A
    Int J Gynecol Pathol; 2010 Mar; 29(2):108-12. PubMed ID: 20173495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.